Immunome

Recent news

• Rating change
  J.P. Morgan Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $39
  Market Newswire · 2026/6/12
• LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/10/6
• Rating change
  Truist Financial Maintains Immunome(IMNM.US) With Buy Rating
  Market Newswire · 2026/7/9
• Rating change
  Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36
  Market Newswire · 2026/6/11
• Rating change
  A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $33 to $40
  Market Newswire · 2026/8/13
• Rating change
  Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)
  TipRanks · 2026/6/12
• Rating change
  J.P. Morgan Maintains Immunome(IMNM.US) With Buy Rating
  Market Newswire · 2026/6/30
• Stifel Initiates Immunome(IMNM.US) With Hold Rating, Announces Target Price $24
  Market Newswire · 2026/10/1
• Rating change
  H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/9/11
• A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32
  Market Newswire · 2026/9/21
• Rating change
  Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
  Market Newswire · 2026/6/1
• Rating change
  Leerink Partners Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $33
  Market Newswire · 2026/5/15
• Rating change
  Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
  TipRanks · 2026/8/12
• Rating change
  Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Immunome (IMNM)
  TipRanks · 2026/9/10
• Rating change
  Lake Street Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/6/1
• Rating change
  Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)
  TipRanks · 2026/7/22
• Rating change
  Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37
  Market Newswire · 2026/5/28
• Rating change
  Goldman Sachs Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $35
  Market Newswire · 2026/5/14
• Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)
  TipRanks · 2026/9/30
• Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36
  Market Newswire · 2026/10/1

Headlines are aggregated automatically and are not independently verified or edited by our team.